B
13.81
-6.30 (-31.33%)
| Previous Close | 20.11 |
| Open | 17.29 |
| Volume | 5,707,402 |
| Avg. Volume (3M) | 542,582 |
| Market Cap | 953,525,312 |
| Price / Sales | 20.96 |
| Price / Book | 1.25 |
| 52 Weeks Range | |
| Earnings Date | 18 Feb 2025 - 24 Feb 2025 |
| Operating Margin (TTM) | -2,385.87% |
| Diluted EPS (TTM) | -3.28 |
| Quarterly Revenue Growth (YOY) | -50.00% |
| Total Debt/Equity (MRQ) | 1.33% |
| Current Ratio (MRQ) | 17.13 |
| Operating Cash Flow (TTM) | -202.62 M |
| Levered Free Cash Flow (TTM) | -141.18 M |
| Return on Assets (TTM) | -15.02% |
| Return on Equity (TTM) | -26.67% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Bicycle Therapeutics plc | Bearish | Bearish |
AIStockmoo Score
1.6
| Analyst Consensus | 3.0 |
| Insider Activity | 4.0 |
| Price Volatility | 5.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -2.5 |
| Average | 1.60 |
|
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.30% |
| % Held by Institutions | 92.37% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tybourne Capital Management (Hk) Ltd | 30 Sep 2024 | 1,394,535 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 38.00 (Needham, 175.16%) | Buy |
| Median | 29.50 (113.61%) | |
| Low | 17.00 (B. Riley Securities, 23.10%) | Hold |
| Average | 29.00 (109.99%) | |
| Total | 4 Buy, 2 Hold | |
| Avg. Price @ Call | 19.23 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 18 Dec 2024 | 26.00 (88.27%) | Buy | 15.32 |
| HC Wainwright & Co. | 16 Dec 2024 | 33.00 (138.96%) | Buy | 15.12 |
| 01 Nov 2024 | 55.00 (298.26%) | Buy | 22.71 | |
| B. Riley Securities | 13 Dec 2024 | 17.00 (23.10%) | Hold | 13.81 |
| Stephens & Co. | 08 Nov 2024 | 25.00 (81.03%) | Hold | 24.96 |
| RBC Capital | 01 Nov 2024 | 35.00 (153.44%) | Buy | 22.71 |
| Needham | 31 Oct 2024 | 38.00 (175.16%) | Buy | 23.45 |
| 24 Oct 2024 | 38.00 (175.16%) | Buy | 24.77 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 14.47 | - | 1,485,397 | 21,168,333 |
| Aggregate Net Quantity | 1,485,397 | |||
| Aggregate Net Value ($) | 21,168,333 | |||
| Aggregate Avg. Buy ($) | 14.47 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Director | 16 Dec 2024 | Buy (+) | 500,000 | 15.12 | 7,560,000 |
| BAKER BROS. ADVISORS LP | Director | 13 Dec 2024 | Buy (+) | 985,397 | 13.81 | 13,608,333 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |